DRI provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets.
DRI Healthcare Trust provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Our business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties with the aim to deliver attractive growth in cash royalty receipts over the long term.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 22, 2021 | Post-IPO Debt | $200M | 3 | CIBC | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
CIBC | Yes | Post-IPO Debt |
Bank of America | — | Post-IPO Debt |
National Bank of Canada | — | Post-IPO Debt |